Top Authors

• Most frequent coverage on SHPGY

• 
  Mark Mitchell (42 followers)

  • Lumizyme Rejected Again: Downgrading Genzyme Recommendation from Buy to Hold (Tue, Nov 17)
  • Genzyme: Focusing on Lumizyme Approval (Fri, Oct 30)
  • Trial Setback Is Welcome News for Genzyme, But Don't Get Too Excited (Tue, Oct 6)

  More by Mark Mitchell on SHPGY »
• 
  Centient Biotech Investor (10 followers)

  • Biotech Day in Review: New River/Shire Win Approval for ADHD Drug (Tue, Feb 27)
  • Biotech Day In Review: Genentech Loses Cabilly Patent Ruling (Thu, Feb 22)
  • Biotech Day in Review: Shire Buys New River for $2.6 Billion (Wed, Feb 21)

  More by Centient Biotech Investor on SHPGY »
• 
  Mike Havrilla (1944 followers)

  • BioMed News: Antigenics, Shire, King Pharma, Delcath Systems (Wed, Oct 21)
  • FDA Calendar Updates: Achillion Pharma, Roche, Genzyme, Protalix, Shire (Fri, Jul 31)
  • FDA Calendar Updates: Schering-Plough, Shire, Elron Electronics, Cardium (Tue, Jul 28)

  More by Mike Havrilla on SHPGY »

• Most followed authors on SHPGY

• 
  Don Dion (2772 followers)

  • Biotech Fund IBB May Ride the M&A Frenzy, but It's Still Wildly Volatile (Thu, Dec 13)

  More by Don Dion on SHPGY »
• 
  Market Folly (2015 followers)

  • Galleon's Q408: SPY Pays Off Alongside Reduced Equity Positions (Tue, Apr 21)
  • Hedge Fund Tracking: Barry Rosenstein's Jana Partners, Q3 2008 (Wed, Dec 24)

  More by Market Folly on SHPGY »
• 
  Mike Havrilla (1944 followers)

  • BioMed News: Antigenics, Shire, King Pharma, Delcath Systems (Wed, Oct 21)
  • FDA Calendar Updates: Achillion Pharma, Roche, Genzyme, Protalix, Shire (Fri, Jul 31)
  • FDA Calendar Updates: Schering-Plough, Shire, Elron Electronics, Cardium (Tue, Jul 28)

  More by Mike Havrilla on SHPGY »

• Newest authors on SHPGY

• 
  Ken Majmudar (10 followers)

  • Genzyme: Short Term Traders Are Throwing Out the Baby with the Bathwater (Wed, Sep 16)

  More by Ken Majmudar on SHPGY »
• 
  BioPharma Investor (76 followers)

  • Protalix Biotherapeutics: FDA Fast Track for Gaucher Treatment (Wed, Aug 26)

  More by BioPharma Investor on SHPGY »
• 
  Mark Mitchell (42 followers)

  • Lumizyme Rejected Again: Downgrading Genzyme Recommendation from Buy to Hold (Tue, Nov 17)
  • Genzyme: Focusing on Lumizyme Approval (Fri, Oct 30)
  • Trial Setback Is Welcome News for Genzyme, But Don't Get Too Excited (Tue, Oct 6)

  More by Mark Mitchell on SHPGY »

• Most commented on SHPGY

• 
  Mike Havrilla (1944 followers)

  • BioMed News: Antigenics, Shire, King Pharma, Delcath Systems (Wed, Oct 21)
  • FDA Calendar Updates: Achillion Pharma, Roche, Genzyme, Protalix, Shire (Fri, Jul 31)
  • FDA Calendar Updates: Schering-Plough, Shire, Elron Electronics, Cardium (Tue, Jul 28)

  More by Mike Havrilla on SHPGY »
• 
  SA Editor Eli Hoffmann (1034 followers)

  • What to Buy and Why: Barron's 2009 Roundtable, Part III (Sun, Jan 25)
  • Barron's 2007 Analyst Roundtable, Part III (Sun, Jan 28)

  More by SA Editor Eli Hoffmann on SHPGY »
• 
  Michael Becker (165 followers)

  • Developments for Parkinson's Disease Ignite Investor Enthusiasm (Mon, Nov 16)
  • Genzyme's Manufacturing Disruption Highlights Investment Opportunities (Mon, Jul 20)
  • Where Might Genentech Investors Redeploy $47B? (Mon, Mar 16)

  More by Michael Becker on SHPGY »